Aim: ASPIRE aims to validate the cost-utility modelling of proton beam therapy (PBT) for specific cancers on the Medicare Benefits Schedule (MBS). This abstract explores the dynamic evolution of the registry, highlighting milestones, learnings, and preliminary insights from the first 50 participants enrolled.
Method: ASPIRE's development extends beyond its observational design, emphasising a collaborative approach. The formation of the ASPIRE National Steering Committee has played a pivotal role in the development of the registry. This committee, meeting regularly, has crafted essential documents, including terms of reference, data access policy, and data access agreements, ensuring a standardised and ethical approach to registry governance.
Learnings from the initial recruitment phase have shaped the registry's trajectory. Data collection strategies continue to evolve, addressing challenges and incorporating feedback. The working groups role in refining these methodologies ensures the registry's adaptability and efficacy.
Results: The initial results from the first 50 participants shed light on treatment patterns, side effects, and outcomes. Simultaneously, the ASPIRE National Steering Committee have facilitated updates on the national rollout, with additional sites in various approval stages.
The ASPIRE Working Group has implemented a range of standard operating procedures for the registry and an integrating recruitment process via the proposed National Referral Portal for the Australian Bragg Centre for Proton Therapy and Research. This inclusion signifies a step towards a more comprehensive understanding of PBT outcomes on a national scale.
Conclusion: Preliminary insights from the first 50 participants highlight the registry's potential to contribute in the areas of treatment efficacy and toxicity. As ASPIRE progresses, the committee's role in the national rollout, site involvement, and integration into referral portals, emphasises a holistic approach to advancing evidence-based cancer care in Australia.